Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication of allogeneic stem cell transplantation, with a cumulative incidence of 1% at 10 years. PTLDs occurring in the first 6-12 months after stem cell transplant usually manifest as clinically aggressive B-cell lymphomas of donor origin, and the majority of these cases are believed to express the B-cell-associated CD20 surface antigen, although only scarce data have been reported. 1, 2 Most of these cases are associated with the Epstein-Barr virus (EBV). They can be polyclonal, oligoclonal, or (less commonly) monoclonal. Known risk factors for the development of early-onset PTLD include T-cell depletion of the graft, matched unrelated donor (MUD) or mismatched related donor transplant, antithymocyte globulin (ATG) therapy for prophylaxis or treatment of graft-versus-host disease (GVHD), and anti-CD3 monoclonal antibody therapy. 1 PTLD is frequently fatal, particularly if not diagnosed at an early stage. Treatment options include chemotherapy, reduction of immunosuppression, and adoptive immunotherapy with donor leukocytes or donor-derived EBVspecific cytotoxic T-lymphocytes. 2, 3 More recently, the anti-CD20 monoclonal antibody rituximab has been employed. 4 We report a case of CD20À polyclonal EBVassociated PTLD.
A 21-year-old man underwent an MUD bone marrow transplant (BMT) for T-cell acute lymphoblastic leukemia. He had a 4-year history of steroid-dependent ulcerative colitis. The conditioning regimen included cyclophosphamide and total body irradiation. The GVHD prophylaxis consisted of tacrolimus and methotrexate.
He engrafted successfully and achieved a hematologic remission. He developed acute GVHD of the skin and gut. His skin GVHD responded to steroid therapy, while his gut GVHD proved steroid refractory at first, and then steroid-dependent. Over the following months, he received daclizumab (two courses) as well as infliximab as steroid-sparing agents. In view of his persistent diarrhea, as well as ongoing steroid and tacrolimus requirement 9 months after his transplant (in addition to severe steroidrelated side effects), he received a 4-day course of ATG (thymoglobulin).
About 4 weeks later, he was presented to our Emergency Center with high fever, hypotension, jaundice, and severe abdominal pain. Laboratory evaluation revealed leukocytosis (29.2 Â 10 9 /l) with 18% 'unclassified', large, transformed, blastic cells with prominent nucleoli and basophilic cytoplasm in the peripheral blood (Figure 1a ), hyperbilirubinemia (mainly direct), coagulopathy, and acute renal failure. Blood cultures were negative, and a chest X-ray showed no infiltrate. A bone marrow aspirate (Figure 1b) showed an extensive infiltrate of polymorphic plasmablastic and plasmacytic cells with basophilic cytoplasm. A sigmoid biopsy on the same day revealed a similar, extensive immunoblastic and lymphoplasmacytic infiltrate in the lamina propria (Figure 1c) .
Recurrence of his original T-cell leukemia was tentatively ruled out and a presumptive diagnosis of PTLD was made, based on the clinical picture and his history of MUD allograft, as well as recent ATG treatment. Pending flow cytometric and immunohistochemical data (as well as EBV data), high-dose methylprednisolone and rituximab were administered. Unfortunately, the patient's condition rapidly deteriorated with pancytopenia, as well as progressive hypotension with profound metabolic acidosis. He eventually died 4 days after he presented to our Emergency Center. Permission for a post-mortem examination was not granted.
Immunohistochemical and flow cytometric studies subsequently showed that greater than 90% of the immunoblastic and plasmacytic infiltrate consisted of polyclonal B cells (by light-chain criteria) with a CD2À, CD19 þ , CD20À, CD38 þ , and CD138 þ immunophenotype (Figure 1d and e) .
EBV status was assessed by in situ hybridization for EBV-encoded small RNA (DAKO) and EBV DNA quantitative PCR. Results of in situ hybridization studies for EBV (EBER) on marrow and sigmoid were strongly positive (Figure 1f ). EBV DNA quantitative PCR titer on a peripheral blood sample drawn on the day after presentation was found to be 10 000 000 copies/ml (reference range: o100 copies/ml).
Initial reports on rituximab activity in patients with PTLD seem very encouraging, although patients with advanced disease and high viral load seem to respond poorly. 4 Therefore, molecular EBV monitoring and preemptive therapy with rituximab in patients at high risk for PTLD and with significant (ie 41000 copies/ml) EBV viremia has been recommended. 5 Unfortunately, this approach was not feasible in our patient, who was no longer being followed at our center.
The CD20 antigen is expressed on the surface of normal B cells from the pre-B-cell to the activated B-cell stage, as well as in more than 90% of B-cell lymphomas. In the Bcell lineage, its expression decreases and essentially ceases with plasma cell differentiation. 6 The marked plasmablastic and plasmacytic differentiation of this patient's PTLD probably accounts for the lack of CD20 reactivity. It may also explain the strong expression of the CD138 antigen, which is known to be present on plasma cells. 7 While it is ordinarily assumed that the majority of PTLD cases are CD20 þ , most reports on PTLD after allogeneic BMT lack relevant immunophenotyping data. In the setting of solid organ transplants, a report on 25 cases showed that 84% of PTLD displayed variable degrees of CD20 expression, while only 16% displayed almost complete absence of CD20 expression. 8 Another study on 17 cases showed diffuse or focal CD20 expression in 15 (88%) and undetectable CD20 expression in two (12%). 9 The molecular histogenesis in these cases is heterogeneous, although CD138 þ cases have been well documented. 10 It is possible that CD20 negativity may account for some instances of lack of response to rituximab.
In conclusion, this case provides a valuable reminder that, as in solid organ transplants, not all cases of PTLDs in the post-BMT setting express the CD20 antigen. Every effort should therefore be made to obtain and review flow cytometric and/or immunophenotyping data in these cases, particularly for cases displaying morphological features suggestive of plasma cell differentiation. 
